CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
On June 13, 2019, CTS provided information regarding the manufacturer’s discontinuation of HIV...
Reminder: On Wednesday August 15, 2018 at 11:00AM PDT, we will be hosting a webinar regarding the ch...
On August 9, 2019, the new CTS Laboratory Information System was successfully implemented in St...
The revised CTS algorithm associated with the Ortho platform is now available for review. Clie...
On December 28, 2021, the FDA updated the emergency use authorization (EUA) for COVID-19 conva...
Daylight Saving Time Begins March 10, 2019. As a friendly reminder, airlines often change their rout...